Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)

Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)

Podrobná bibliografie
Hlavní autoři: Dutton, S, Blazeby, J, Petty, R, Mansoor, W, Thompson, J, Harrison, M, Abbas, H, Dahle-Smith, A, Chatterjee, A, Falk, S, Garcia-Alonso, A, Fyfe, D, Hubner, R, Gamble, T, Peachey, L, Harvey, C, Julier, P, Jankowski, J, Midgley, R, Ferry, DR, Grp, C
Médium: Journal article
Vydáno: 2013
Popis
Shrnutí:

Podobné jednotky